These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11176816)

  • 21. Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients.
    Taliani G; Gemignani G; Ferrari C; Aceti A; Bartolozzi D; Blanc PL; Capanni M; Esperti F; Forte P; Guadagnino V; Mari T; Marino N; Milani S; Pasquazzi C; Rosina F; Tacconi D; Toti M; Zignego AL; Messerini L; Stroffolini T;
    Gastroenterology; 2006 Apr; 130(4):1098-106. PubMed ID: 16618404
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patterns of response during therapy with interferon and outcome of retreatment with interferon plus ribavirin for chronic hepatitis C.
    Ogana G; Tocco A; Garrucciu G; Branca B; Azara V; Manzoni NE; Deplano A; Solinas A
    J Clin Gastroenterol; 2001 Sep; 33(3):254-5. PubMed ID: 11500622
    [No Abstract]   [Full Text] [Related]  

  • 23. Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?
    Zeuzem S
    Ann Intern Med; 2004 Mar; 140(5):370-81. PubMed ID: 14996679
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Chronic hepatitis C and B. What can be accomplished with antiviral therapy].
    MMW Fortschr Med; 2007 Feb; 149(7):14. PubMed ID: 17615650
    [No Abstract]   [Full Text] [Related]  

  • 25. Hepatitis C: current and future therapies.
    Mishra P; Jensen DM
    Mt Sinai J Med; 2008 Aug; 75(4):405-14. PubMed ID: 18729159
    [No Abstract]   [Full Text] [Related]  

  • 26. Current treatment for chronic hepatitis C.
    Davis GL
    Rev Gastroenterol Disord; 2001; 1(2):59-72. PubMed ID: 12120176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High body mass index is an independent risk factor for nonresponse to antiviral treatment in chronic hepatitis C.
    Bressler BL; Guindi M; Tomlinson G; Heathcote J
    Hepatology; 2003 Sep; 38(3):639-44. PubMed ID: 12939590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of interferon and ribavirin in chronic hepatitis C: re-treatment of nonresponders to interferon.
    Di Bisceglie AM; Thompson J; Smith-Wilkaitis N; Brunt EM; Bacon BR
    Hepatology; 2001 Mar; 33(3):704-7. PubMed ID: 11230751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop.
    Chung RT; Gale M; Polyak SJ; Lemon SM; Liang TJ; Hoofnagle JH
    Hepatology; 2008 Jan; 47(1):306-20. PubMed ID: 18161743
    [No Abstract]   [Full Text] [Related]  

  • 30. Combination therapy with interferon and ribavirin in the treatment of chronic hepatitis C infection.
    Battaglia AM; Hagmeyer KO
    Ann Pharmacother; 2000 Apr; 34(4):487-94. PubMed ID: 10772437
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interleukin-22 and Chemokine Interferon γ -Inducible-10 (IP-10) Levels in Chronic Hepatitis C Patients and Treatment Response to Pegylated Interferon and Ribavirin Therapy.
    F GM; Attia FM; Saleh RM; M H; Anani M
    Egypt J Immunol; 2017 Jun; 24(2):83-91. PubMed ID: 29528582
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Quality of life of patients with chronic hepatitis C: effect of treatments].
    Couzigou P
    Gastroenterol Clin Biol; 2002 Apr; 26 Spec No 2():B257-63. PubMed ID: 12180299
    [No Abstract]   [Full Text] [Related]  

  • 33. Treatment options for patients with chronic hepatitis C not responding to initial antiviral therapy.
    Jacobson IM
    Clin Gastroenterol Hepatol; 2009 Sep; 7(9):921-30. PubMed ID: 19362605
    [No Abstract]   [Full Text] [Related]  

  • 34. An artificial neural network approach to the drug efficacy of interferon treatments.
    Lin E; Hwang Y; Wang SC; Gu ZJ; Chen EY
    Pharmacogenomics; 2006 Oct; 7(7):1017-24. PubMed ID: 17054412
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of adding ribavirin to interferon to treat chronic hepatitis C infection: a systematic review and meta-analysis of randomized trials.
    Brok J; Gluud LL; Gluud C
    Arch Intern Med; 2005 Oct; 165(19):2206-12. PubMed ID: 16246984
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The response to interferon + ribavirin re-treatment for chronic hepatitis C in interferon non-responders is not influenced by race.
    De Maria N; Colantoni A; Idilman R; Harig J; Van Thiel DH
    J Hepatol; 2000 Dec; 33(6):1028-9. PubMed ID: 11131445
    [No Abstract]   [Full Text] [Related]  

  • 37. Should routine screening for coeliac disease be considered before starting interferon/ribavirin treatment in patients affected by chronic hepatitis C?
    Casella G; Bardella MT; Perego D; Baldini V
    Eur J Gastroenterol Hepatol; 2004 Apr; 16(4):429. PubMed ID: 15028979
    [No Abstract]   [Full Text] [Related]  

  • 38. Ribavirin plus interferon versus interferon for chronic hepatitis C.
    Brok J; Gluud LL; Gluud C
    Cochrane Database Syst Rev; 2005 Jul; (3):CD005445. PubMed ID: 16034976
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Triple antiviral therapy as a new option for patients with interferon nonresponsive chronic hepatitis C.
    Brillanti S; Levantesi F; Masi L; Foli M; Bolondi L
    Hepatology; 2000 Sep; 32(3):630-4. PubMed ID: 10960460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Meta-analysis: re-treatment of genotype I hepatitis C nonresponders and relapsers after failing interferon and ribavirin combination therapy.
    Singal AG; Waljee AK; Shiffman M; Bacon BR; Schoenfeld PS
    Aliment Pharmacol Ther; 2010 Oct; 32(8):969-83. PubMed ID: 20937042
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.